Antidiabetic effects and safety profile of chitosan delivery systems loaded with new xanthine-thiazolidine-4-one derivatives: in vivo studies
Based on important biological effects associated with xanthine and thiazolidine-4-one moieties, especially hypoglycemic and antioxidant, new xanthine derivatives with thiazolidine-4-one scaffold (XTDs, 6a-k) have been synthesized and reported by our research group, as new potential multitarget antid...
Gespeichert in:
Veröffentlicht in: | Journal of drug delivery science and technology 2020-12, Vol.60, p.102091, Article 102091 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 102091 |
container_title | Journal of drug delivery science and technology |
container_volume | 60 |
creator | Constantin, Sandra Madalina Lupascu, Florentina Geanina Apotrosoaei, Maria Focsa, Alin Viorel Vasincu, Ioana Mirela Confederat, Luminita Georgeta Dimitriu, Gabriel Lupusoru, Catalina Elena Routier, Sylvain Buron, Frederic Profire, Lenuta |
description | Based on important biological effects associated with xanthine and thiazolidine-4-one moieties, especially hypoglycemic and antioxidant, new xanthine derivatives with thiazolidine-4-one scaffold (XTDs, 6a-k) have been synthesized and reported by our research group, as new potential multitarget antidiabetic drugs. The goal of this work was to evaluate the in vivo antidiabetic potential and safety profile of the most proper XTDs (6c, 6e) and their chitosan based formulations, CS-XTDs (CS-6c, CS-6e) selected based on previous results in terms of their in vitro antioxidant effects and physic-chemical characteristics. Using a streptozotocin-induced diabetes model, the hypoglycemic effect (postprandial glycemia and glycated hemoglobin), biochemical markers of liver and kidney function, as well as hematological markers have been evaluated. The effect on lipid profile and clinical parameters (body weight, food, and water intake) has been also monitored. Moreover, the biopharmaceutical characteristics of 6c and 6e were predicted using in silico computerized methods. The treatment of diabetic rats with CS-XTDs, especially CS-6c was associated with appreciable hypoglycemic effect, the values of postprandial glycemia and glycated hemoglobin being similar with pioglitazone, used as reference drug. In addition, the recorded values for liver enzymes (AST, ALT, LDH), bilirubin (direct, total) and kidney biochemical markers (creatinine, uric acid, urea) were also comparable with pioglitazone. Also, CS-6c was associated with good hematological markers and clinical parameters. The results highlighted the efficiency of the developed chitosan delivery system CS-6c for the treatment of diabetes mellitus syndrome, acting as a potential multitarget agent.
[Display omitted]
•Chitosan proved to be suitable as drug delivery systems for diabetes mellitus therapy.•Xanthine-thiazolidine-4-one derivatives showed improved hypoglycemic effect.•Chloro substituent showed a favorable influence for hypoglycemic effect.•Improvement of renal, liver and cardiovascular damage specific to diabetes mellitus. |
doi_str_mv | 10.1016/j.jddst.2020.102091 |
format | Article |
fullrecord | <record><control><sourceid>elsevier_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04451428v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1773224720313800</els_id><sourcerecordid>S1773224720313800</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-d3cc0b6fae6e0d259604fc5abc440b6a55fbd88ec8f058add787b5403effb9673</originalsourceid><addsrcrecordid>eNp9kM9KAzEQh_egYKl9Ai-5etia7Gb_VPBQilqh4EXPIZtM6JRtUpK4ur6D72xqxaOXCfNjvgnzZdkVo3NGWX2zm--0DnFe0OKYFHTBzrIJa5oyLwreXGSzEHaUUtZQxovFJPta2ogaZQcRFQFjQMVApNUkSANxJAfvDPZAnCFqi9EFaYmGHgfwIwljiLAPpHdSgybvGLfEwjv5kDZu0UKeqvx0ffohNTx3FhLscZAxLQi3BC0ZcHAkxDeNEC6zcyP7ALPfd5q9Pty_rNb55vnxabXc5Kosm5jrUina1UZCDVQX1aKm3KhKdorzlMuqMp1uW1CtoVUrtW7apqs4LdN93aJuyml2fdq7lb04eNxLPwonUayXG3HMKOdVEtQOLM2Wp1nlXQgezB_AqDhKFzvxI10cpYuT9ETdnShIZwwIXgSFYBVo9Emx0A7_5b8Bm2ORZg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Antidiabetic effects and safety profile of chitosan delivery systems loaded with new xanthine-thiazolidine-4-one derivatives: in vivo studies</title><source>Alma/SFX Local Collection</source><creator>Constantin, Sandra Madalina ; Lupascu, Florentina Geanina ; Apotrosoaei, Maria ; Focsa, Alin Viorel ; Vasincu, Ioana Mirela ; Confederat, Luminita Georgeta ; Dimitriu, Gabriel ; Lupusoru, Catalina Elena ; Routier, Sylvain ; Buron, Frederic ; Profire, Lenuta</creator><creatorcontrib>Constantin, Sandra Madalina ; Lupascu, Florentina Geanina ; Apotrosoaei, Maria ; Focsa, Alin Viorel ; Vasincu, Ioana Mirela ; Confederat, Luminita Georgeta ; Dimitriu, Gabriel ; Lupusoru, Catalina Elena ; Routier, Sylvain ; Buron, Frederic ; Profire, Lenuta</creatorcontrib><description>Based on important biological effects associated with xanthine and thiazolidine-4-one moieties, especially hypoglycemic and antioxidant, new xanthine derivatives with thiazolidine-4-one scaffold (XTDs, 6a-k) have been synthesized and reported by our research group, as new potential multitarget antidiabetic drugs. The goal of this work was to evaluate the in vivo antidiabetic potential and safety profile of the most proper XTDs (6c, 6e) and their chitosan based formulations, CS-XTDs (CS-6c, CS-6e) selected based on previous results in terms of their in vitro antioxidant effects and physic-chemical characteristics. Using a streptozotocin-induced diabetes model, the hypoglycemic effect (postprandial glycemia and glycated hemoglobin), biochemical markers of liver and kidney function, as well as hematological markers have been evaluated. The effect on lipid profile and clinical parameters (body weight, food, and water intake) has been also monitored. Moreover, the biopharmaceutical characteristics of 6c and 6e were predicted using in silico computerized methods. The treatment of diabetic rats with CS-XTDs, especially CS-6c was associated with appreciable hypoglycemic effect, the values of postprandial glycemia and glycated hemoglobin being similar with pioglitazone, used as reference drug. In addition, the recorded values for liver enzymes (AST, ALT, LDH), bilirubin (direct, total) and kidney biochemical markers (creatinine, uric acid, urea) were also comparable with pioglitazone. Also, CS-6c was associated with good hematological markers and clinical parameters. The results highlighted the efficiency of the developed chitosan delivery system CS-6c for the treatment of diabetes mellitus syndrome, acting as a potential multitarget agent.
[Display omitted]
•Chitosan proved to be suitable as drug delivery systems for diabetes mellitus therapy.•Xanthine-thiazolidine-4-one derivatives showed improved hypoglycemic effect.•Chloro substituent showed a favorable influence for hypoglycemic effect.•Improvement of renal, liver and cardiovascular damage specific to diabetes mellitus.</description><identifier>ISSN: 1773-2247</identifier><identifier>DOI: 10.1016/j.jddst.2020.102091</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Chemical Sciences ; Chitosan ; Diabetes mellitus ; Drug delivery systems ; Medicinal Chemistry ; Microparticles ; Organic chemistry ; Streptozotocin ; Thiazolidine-4-one scaffold</subject><ispartof>Journal of drug delivery science and technology, 2020-12, Vol.60, p.102091, Article 102091</ispartof><rights>2020 Elsevier B.V.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-d3cc0b6fae6e0d259604fc5abc440b6a55fbd88ec8f058add787b5403effb9673</citedby><cites>FETCH-LOGICAL-c337t-d3cc0b6fae6e0d259604fc5abc440b6a55fbd88ec8f058add787b5403effb9673</cites><orcidid>0000-0001-5773-1515 ; 0000-0002-2823-0591</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://hal.science/hal-04451428$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Constantin, Sandra Madalina</creatorcontrib><creatorcontrib>Lupascu, Florentina Geanina</creatorcontrib><creatorcontrib>Apotrosoaei, Maria</creatorcontrib><creatorcontrib>Focsa, Alin Viorel</creatorcontrib><creatorcontrib>Vasincu, Ioana Mirela</creatorcontrib><creatorcontrib>Confederat, Luminita Georgeta</creatorcontrib><creatorcontrib>Dimitriu, Gabriel</creatorcontrib><creatorcontrib>Lupusoru, Catalina Elena</creatorcontrib><creatorcontrib>Routier, Sylvain</creatorcontrib><creatorcontrib>Buron, Frederic</creatorcontrib><creatorcontrib>Profire, Lenuta</creatorcontrib><title>Antidiabetic effects and safety profile of chitosan delivery systems loaded with new xanthine-thiazolidine-4-one derivatives: in vivo studies</title><title>Journal of drug delivery science and technology</title><description>Based on important biological effects associated with xanthine and thiazolidine-4-one moieties, especially hypoglycemic and antioxidant, new xanthine derivatives with thiazolidine-4-one scaffold (XTDs, 6a-k) have been synthesized and reported by our research group, as new potential multitarget antidiabetic drugs. The goal of this work was to evaluate the in vivo antidiabetic potential and safety profile of the most proper XTDs (6c, 6e) and their chitosan based formulations, CS-XTDs (CS-6c, CS-6e) selected based on previous results in terms of their in vitro antioxidant effects and physic-chemical characteristics. Using a streptozotocin-induced diabetes model, the hypoglycemic effect (postprandial glycemia and glycated hemoglobin), biochemical markers of liver and kidney function, as well as hematological markers have been evaluated. The effect on lipid profile and clinical parameters (body weight, food, and water intake) has been also monitored. Moreover, the biopharmaceutical characteristics of 6c and 6e were predicted using in silico computerized methods. The treatment of diabetic rats with CS-XTDs, especially CS-6c was associated with appreciable hypoglycemic effect, the values of postprandial glycemia and glycated hemoglobin being similar with pioglitazone, used as reference drug. In addition, the recorded values for liver enzymes (AST, ALT, LDH), bilirubin (direct, total) and kidney biochemical markers (creatinine, uric acid, urea) were also comparable with pioglitazone. Also, CS-6c was associated with good hematological markers and clinical parameters. The results highlighted the efficiency of the developed chitosan delivery system CS-6c for the treatment of diabetes mellitus syndrome, acting as a potential multitarget agent.
[Display omitted]
•Chitosan proved to be suitable as drug delivery systems for diabetes mellitus therapy.•Xanthine-thiazolidine-4-one derivatives showed improved hypoglycemic effect.•Chloro substituent showed a favorable influence for hypoglycemic effect.•Improvement of renal, liver and cardiovascular damage specific to diabetes mellitus.</description><subject>Chemical Sciences</subject><subject>Chitosan</subject><subject>Diabetes mellitus</subject><subject>Drug delivery systems</subject><subject>Medicinal Chemistry</subject><subject>Microparticles</subject><subject>Organic chemistry</subject><subject>Streptozotocin</subject><subject>Thiazolidine-4-one scaffold</subject><issn>1773-2247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kM9KAzEQh_egYKl9Ai-5etia7Gb_VPBQilqh4EXPIZtM6JRtUpK4ur6D72xqxaOXCfNjvgnzZdkVo3NGWX2zm--0DnFe0OKYFHTBzrIJa5oyLwreXGSzEHaUUtZQxovFJPta2ogaZQcRFQFjQMVApNUkSANxJAfvDPZAnCFqi9EFaYmGHgfwIwljiLAPpHdSgybvGLfEwjv5kDZu0UKeqvx0ffohNTx3FhLscZAxLQi3BC0ZcHAkxDeNEC6zcyP7ALPfd5q9Pty_rNb55vnxabXc5Kosm5jrUina1UZCDVQX1aKm3KhKdorzlMuqMp1uW1CtoVUrtW7apqs4LdN93aJuyml2fdq7lb04eNxLPwonUayXG3HMKOdVEtQOLM2Wp1nlXQgezB_AqDhKFzvxI10cpYuT9ETdnShIZwwIXgSFYBVo9Emx0A7_5b8Bm2ORZg</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Constantin, Sandra Madalina</creator><creator>Lupascu, Florentina Geanina</creator><creator>Apotrosoaei, Maria</creator><creator>Focsa, Alin Viorel</creator><creator>Vasincu, Ioana Mirela</creator><creator>Confederat, Luminita Georgeta</creator><creator>Dimitriu, Gabriel</creator><creator>Lupusoru, Catalina Elena</creator><creator>Routier, Sylvain</creator><creator>Buron, Frederic</creator><creator>Profire, Lenuta</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-5773-1515</orcidid><orcidid>https://orcid.org/0000-0002-2823-0591</orcidid></search><sort><creationdate>202012</creationdate><title>Antidiabetic effects and safety profile of chitosan delivery systems loaded with new xanthine-thiazolidine-4-one derivatives: in vivo studies</title><author>Constantin, Sandra Madalina ; Lupascu, Florentina Geanina ; Apotrosoaei, Maria ; Focsa, Alin Viorel ; Vasincu, Ioana Mirela ; Confederat, Luminita Georgeta ; Dimitriu, Gabriel ; Lupusoru, Catalina Elena ; Routier, Sylvain ; Buron, Frederic ; Profire, Lenuta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-d3cc0b6fae6e0d259604fc5abc440b6a55fbd88ec8f058add787b5403effb9673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Chemical Sciences</topic><topic>Chitosan</topic><topic>Diabetes mellitus</topic><topic>Drug delivery systems</topic><topic>Medicinal Chemistry</topic><topic>Microparticles</topic><topic>Organic chemistry</topic><topic>Streptozotocin</topic><topic>Thiazolidine-4-one scaffold</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Constantin, Sandra Madalina</creatorcontrib><creatorcontrib>Lupascu, Florentina Geanina</creatorcontrib><creatorcontrib>Apotrosoaei, Maria</creatorcontrib><creatorcontrib>Focsa, Alin Viorel</creatorcontrib><creatorcontrib>Vasincu, Ioana Mirela</creatorcontrib><creatorcontrib>Confederat, Luminita Georgeta</creatorcontrib><creatorcontrib>Dimitriu, Gabriel</creatorcontrib><creatorcontrib>Lupusoru, Catalina Elena</creatorcontrib><creatorcontrib>Routier, Sylvain</creatorcontrib><creatorcontrib>Buron, Frederic</creatorcontrib><creatorcontrib>Profire, Lenuta</creatorcontrib><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Journal of drug delivery science and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Constantin, Sandra Madalina</au><au>Lupascu, Florentina Geanina</au><au>Apotrosoaei, Maria</au><au>Focsa, Alin Viorel</au><au>Vasincu, Ioana Mirela</au><au>Confederat, Luminita Georgeta</au><au>Dimitriu, Gabriel</au><au>Lupusoru, Catalina Elena</au><au>Routier, Sylvain</au><au>Buron, Frederic</au><au>Profire, Lenuta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antidiabetic effects and safety profile of chitosan delivery systems loaded with new xanthine-thiazolidine-4-one derivatives: in vivo studies</atitle><jtitle>Journal of drug delivery science and technology</jtitle><date>2020-12</date><risdate>2020</risdate><volume>60</volume><spage>102091</spage><pages>102091-</pages><artnum>102091</artnum><issn>1773-2247</issn><abstract>Based on important biological effects associated with xanthine and thiazolidine-4-one moieties, especially hypoglycemic and antioxidant, new xanthine derivatives with thiazolidine-4-one scaffold (XTDs, 6a-k) have been synthesized and reported by our research group, as new potential multitarget antidiabetic drugs. The goal of this work was to evaluate the in vivo antidiabetic potential and safety profile of the most proper XTDs (6c, 6e) and their chitosan based formulations, CS-XTDs (CS-6c, CS-6e) selected based on previous results in terms of their in vitro antioxidant effects and physic-chemical characteristics. Using a streptozotocin-induced diabetes model, the hypoglycemic effect (postprandial glycemia and glycated hemoglobin), biochemical markers of liver and kidney function, as well as hematological markers have been evaluated. The effect on lipid profile and clinical parameters (body weight, food, and water intake) has been also monitored. Moreover, the biopharmaceutical characteristics of 6c and 6e were predicted using in silico computerized methods. The treatment of diabetic rats with CS-XTDs, especially CS-6c was associated with appreciable hypoglycemic effect, the values of postprandial glycemia and glycated hemoglobin being similar with pioglitazone, used as reference drug. In addition, the recorded values for liver enzymes (AST, ALT, LDH), bilirubin (direct, total) and kidney biochemical markers (creatinine, uric acid, urea) were also comparable with pioglitazone. Also, CS-6c was associated with good hematological markers and clinical parameters. The results highlighted the efficiency of the developed chitosan delivery system CS-6c for the treatment of diabetes mellitus syndrome, acting as a potential multitarget agent.
[Display omitted]
•Chitosan proved to be suitable as drug delivery systems for diabetes mellitus therapy.•Xanthine-thiazolidine-4-one derivatives showed improved hypoglycemic effect.•Chloro substituent showed a favorable influence for hypoglycemic effect.•Improvement of renal, liver and cardiovascular damage specific to diabetes mellitus.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.jddst.2020.102091</doi><orcidid>https://orcid.org/0000-0001-5773-1515</orcidid><orcidid>https://orcid.org/0000-0002-2823-0591</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1773-2247 |
ispartof | Journal of drug delivery science and technology, 2020-12, Vol.60, p.102091, Article 102091 |
issn | 1773-2247 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_04451428v1 |
source | Alma/SFX Local Collection |
subjects | Chemical Sciences Chitosan Diabetes mellitus Drug delivery systems Medicinal Chemistry Microparticles Organic chemistry Streptozotocin Thiazolidine-4-one scaffold |
title | Antidiabetic effects and safety profile of chitosan delivery systems loaded with new xanthine-thiazolidine-4-one derivatives: in vivo studies |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T01%3A58%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antidiabetic%20effects%20and%20safety%20profile%20of%20chitosan%20delivery%20systems%20loaded%20with%20new%20xanthine-thiazolidine-4-one%20derivatives:%20in%20vivo%20studies&rft.jtitle=Journal%20of%20drug%20delivery%20science%20and%20technology&rft.au=Constantin,%20Sandra%20Madalina&rft.date=2020-12&rft.volume=60&rft.spage=102091&rft.pages=102091-&rft.artnum=102091&rft.issn=1773-2247&rft_id=info:doi/10.1016/j.jddst.2020.102091&rft_dat=%3Celsevier_hal_p%3ES1773224720313800%3C/elsevier_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S1773224720313800&rfr_iscdi=true |